Literature DB >> 11323358

A comparison of 0.0625% bupivacaine with fentanyl and 0.1% ropivacaine with fentanyl for continuous epidural labor analgesia.

J Fernández-Guisasola1, M L Serrano, B Cobo, L Muñoz, A Plaza, C Trigo, S G Del Valle.   

Abstract

UNLABELLED: We compared the analgesic efficacy and the degree of motor block achieved with epidural infusion of 0.0625% bupivacaine (Group B) versus 0.1% ropivacaine (Group R), both with 0.0002% fentanyl (2 microg/mL) in laboring patients. A prospective, double-blinded study was performed in 98 ASA physical status I-II parturients who were divided randomly into two groups to receive either bupivacaine or ropivacaine after catheter location had been tested with an initial bolus of lidocaine and fentanyl. The infusion rate was 15 mL/h in every case. When pain was perceived, 5-mL boluses of the assigned epidural analgesic were administered every 10 min until analgesia was achieved. We recorded pain intensity, level of sensory block, degree of motor block, hemodynamic variables, secondary effects, mode of delivery, neonatal outcome, and patient satisfaction. There were no statistically significant differences in any of the factors analyzed. Highly effective analgesia was achieved in both groups with a small incidence of motor block. These findings suggest that bupivacaine may be more potent than ropivacaine. IMPLICATIONS: We compared different concentrations of epidural bupivacaine and ropivacaine thought to be equipotent. Both solutions were equally efficient in providing highly effective epidural analgesia for labor with minimal motor block. These findings suggest that bupivacaine may be more potent than ropivacaine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323358     DOI: 10.1097/00000539-200105000-00034

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  Epidural analgesia for childbirth: effects of newer techniques on neonatal outcome.

Authors:  Giorgio Capogna; Michela Camorcia
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

2.  Analgesic and motor effects of a high-volume intercoccygeal epidural injection of 0.125% or 0.0625% bupivacaine in adult cows.

Authors:  Eva Rioja; Luis M Rubio-Martínez; Gabrielle Monteith; Carolyn L Kerr
Journal:  Can J Vet Res       Date:  2013-10       Impact factor: 1.310

3.  Comparative evaluation of epidural bupivacaine - dexmedetomidine and bupivacaine -fentanyl on Doppler velocimetry of uterine and umbilical arteries during labor.

Authors:  Mohamed Fouad Selim; Ali Mohamed Ali Elnabtity; Ali Mohamed Ali Hasan
Journal:  J Prenat Med       Date:  2012-07

4.  Epidural analgesia with amide local anesthetics, bupivacaine, and ropivacaine in combination with fentanyl for labor pain relief: a meta-analysis.

Authors:  Yiyang Li; Cong Hu; Yanyan Fan; Huixia Wang; Hongmei Xu
Journal:  Med Sci Monit       Date:  2015-03-29

5.  A comparison of continuous infusion and intermittent bolus administration of 0.1% ropivacaine with 0.0002% fentanyl for epidural labor analgesia.

Authors:  Chinmayi Surendra Patkar; Kalpana Vora; Harshal Patel; Veena Shah; Manisha Pranjal Modi; Geeta Parikh
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Apr-Jun

6.  Epidural Analgesia With Bupivacaine and Fentanyl Versus Ropivacaine and Fentanyl for Pain Relief in Labor: A Meta-Analysis.

Authors:  Shanbin Guo; Bo Li; Chengjie Gao; Yue Tian
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

7.  Comparative Study of Bupivacaine-Fentanyl versus Ropivacaine-Fentanyl for Epidural Analgesia in Labor.

Authors:  Upasna Bhatia; Vandana Shah; Ekta S Soni; Manan Bajaj; Kirti D Patel; Charu J Pandya; Harish Vasaiya
Journal:  Anesth Essays Res       Date:  2022-02-07

Review 8.  Update on the clinical utility and practical use of ropivacaine in Chinese patients.

Authors:  Man Li; Li Wan; Wei Mei; Yuke Tian
Journal:  Drug Des Devel Ther       Date:  2014-09-09       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.